Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health Plc LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -18.00 -6.34% 266.00 349,071 16:35:00
Bid Price Offer Price High Price Low Price Open Price
260.00 270.00 285.00 246.00 285.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 12.84 -53.67 -12.55 752
Last Trade Time Trade Type Trade Size Trade Price Currency
16:59:29 O 1,261 267.269 GBX

Puretech Health (PRTC) Latest News

More Puretech Health News
Puretech Health Takeover Rumours

Puretech Health (PRTC) Share Charts

1 Year Puretech Health Chart

1 Year Puretech Health Chart

1 Month Puretech Health Chart

1 Month Puretech Health Chart

Intraday Puretech Health Chart

Intraday Puretech Health Chart

Puretech Health (PRTC) Discussions and Chat

Puretech Health Forums and Chat

Date Time Title Posts
05/9/201914:20PureTech Health - innovative healthcare407
22/7/201821:35PureTech Health (PRTC) One to Watch Monday -

Add a New Thread

Puretech Health (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-09-20 15:59:29267.271,2613,370.26O
2019-09-20 15:56:57266.03100266.03O
2019-09-20 15:48:10266.004081,085.28O
View all Puretech Health trades in real-time

Puretech Health (PRTC) Top Chat Posts

Puretech Health Daily Update: Puretech Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 284p.
Puretech Health Plc has a 4 week average price of 246p and a 12 week average price of 220p.
The 1 year high share price is 307p while the 1 year low share price is currently 155p.
There are currently 282,679,696 shares in issue and the average daily traded volume is 73,291 shares. The market capitalisation of Puretech Health Plc is £751,927,991.36.
lendmeafiver: I agree, always been very impressed by Daphne Zohar. Share price seems to be going vertical.
lendmeafiver: Yes I had noticed Woodford wasn’t in here, share price flying again.
lendmeafiver: Agree. Surely given recent progress an ipo or other transaction at Gelesis has to be on the cards, will have a huge impact on the Prtc share price I expect.
lendmeafiver: Been looking forward to the approval of Gelesis100 and pleased to see it has created a bit of interest here. When I first invested here I took the view that Gelesis very much covered the downside with all the other puretech pipelines being almost for free in the share price, I very much believe that to be the case now in my opinion. Like the name Plenity also.
rambutan2: Just reminding myself that: PureTech's percentage ownership of Gelesis is approximately 20.5% on a diluted basis and approximately 19.2% on a fully-diluted basis. Note that: PureTech also has the right to receive a 2% royalty on the sales of certain Gelesis products, including Gelesis100 (aka PLENITY).
rambutan2: edwardt, i suppose it's in response to this capital raise... Although in the results they said... "Cash and Cash Equivalents: Cash, cash equivalents and marketable securities were $108.0 million as of December 31, 2018, as compared to $53.3 million as of December 31, 2017. The Company expects that current cash, cash equivalents and marketable securities as of December 31, 2018 will be sufficient to fund its operating expenses at least into the second quarter of 2020." So it's not as though they are desperate. Ultimately, of course, the share price will be trial results driven.
lendmeafiver: Vedanta puretech holding was 71.5% I believe, now 63%, they raised usd27, values the company at around usd200m and puretechs holding at circa usd120m fully diluted, about right? Worth about 45p per share alone, please note calculated on an iPhone calculator whilst drinking in a coffee shop so please correct me if I’m wrong! Very encouraging to see some very high profile new investors directly into Vedanta. Anyway I think it’s been a very sold year of progress here, both in the business and a reasonable share price performance, remains hugely undervalued in my opinion, plenty to look forward to in 2019.
lendmeafiver: Very encouraging news, I purchased a few more here this week, well below ipo and share issue prices of course, I expect that at some stage this year there will be sufficient newsflow to really move the share price closer to the brokers targets of circa £3
edwardt: my takes were chances of two more ipos in next 6 months. they are also going to go coy on valuation methodology given sensitivity around pricing on ipo and second rounds - all makes sense to me but will prove hard for analysts to model which could result in vol in share price. i want to sit tight for a decade on this one.
healzo2: I imagine pretty much as you would expect. Great emphasis placed on the award winning, world class calibre of the team, and the pipeline of innovative and potentially lucrative products. Biome / second brain considerations seen as becoming more prominent in public consciousness going forward. Share price seen as heading upwards of 800p in the next 5 years. Possible headwinds listed as the need for further capitalisation and naturally testing failures. One of the better and more convincingly written pamphlets I've read over the years. Seemed based on true conviction rather than usual ramping rubbish.
Puretech Health share price data is direct from the London Stock Exchange
Your Recent History
Puretech H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190921 15:59:54